Introduction
gastric cancer is the fourth most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide due to its frequency, poor prognosis and limited treatment options (Compare et al. 2010; Jemal et al. 2011; Kamangar et al. 2006) . Complete resection of the tumor and adjacent lymph nodes is the only effective curative treatment (Dikken et al. 2011) . however, after a complete resection,
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Purpose the heat shock protein 22 (hsP22) is associated with tumor proliferation and protects tumor cell from apoptosis in many malignancies. however, the role of hsP22 in gastric cancer has not been thoroughly elucidated. the aim was to determine the relationship of hsP22 expression with clinicopathological parameters and prognosis in gastric cancer and estimate the alteration of hsP22 expression after neoadjuvant chemotherapy. Methods hsP22 and matrix metallopeptidase 9 (MMP-9) antigen expressions were evaluated by immunohistochemistry in 129 gastric carcinoma samples. Univariate and multivariate analyses were performed to determine the association between hsP22 expression and prognosis. the response of hsP22 was assessed in 47 patients who received neoadjuvant chemotherapy. Results hsP22 protein expression was significantly associated with tumor size, depth invasion, lymph node metastasis and stage of disease (all P < 0.05). In univariate and multivariate analyses, hsP22 was an independent prognostic factor for both overall survival (Os) and recurrence-free the 5-year survival rate remains low, which reported to be only 23 % (Cunningham et al. 2006 ). In addition, even the addition of novel, molecularly targeted therapies to standard chemotherapy provide only a limited survival benefit (Bang et al. 2010) . therefore, the identification of novel biomarkers to predict prognosis is important to advance the treatment of patients with gastric cancer.
heat shock proteins (hsPs) are a set of evolutionarily conserved proteins. hsPs have been classified into various subfamilies based on their molecular weight. Broadly, in mammals, four major families of hsPs are recognized: hsP90 (hsP90α, hsP90β, gRP94), hsP70 (hsP70, hsC70, mhsP70, gRP78), hsP60 and small hsPs (hsP27, αB-crystallin, hsP22). accumulation of misfolded protein in stressed cells triggers expressions of hsPs, which prevent protein aggregation and facilitate refolding or elimination of misfolded proteins in their capacities as chaperones (Kim et al. 2007) . Recently, it has been reported that hsPs are significantly associated with cancers (Calderwood et al. 2006) . hsP22 (synonyms: hspB22, e2Ig1, h11), whose molecular mass close to 22 kDa, contains the conserved α-crystallin domain in their C-terminal domain, common among all shsP and is closely related to other shsP such as hsP27 (sun et al. 2004) . hsP22 is thought to belong to the group of "intrinsically disordered proteins" involved in recognition, regulation and cell signaling (Uversky et al. 2005) and possesses a flexible structure. the expression of hsP22 is observed in the majority of tissues, especially in striated and smooth muscles (sun et al. 2004 ). In addition, hsP22 is overexpressed and possesses an anti-apoptotic activity in various types of cancer cells (gober et al. 2005) . For instance, treatment of human breast cancer cell line MCF-7 with 17b-estradiol and cyclin D1 induced up-regulation of certain genes including hsP22 through erB1/erB2 signaling (Yang et al. 2006) . Consistently, numerous data have described hsP22 overexpression association with tumor proliferation and protection from apoptosis of glioblastoma, melanoma and breast cancer cells by cell cycle regulation (Charpentier et al. 2000; Modem et al. 2011; smith et al. 2000) . however, the role of hsP22 expression on the prognosis of patients with gastric cancer remains unclear. therefore, the aim of our study was to evaluate whether hsP22 overexpression is associated with clinicopathological parameters and prognosis of gastric cancer and examine the response of hsP22 expression in neoadjuvant chemotherapy.
Patients and methods
Patients and specimens the study was approved by the Institutional Review Board and human ethics Committee of affiliated hospital of guilin Medical University. Written consent for using the samples for research purposes was obtained from all patients prior to surgery. gastric carcinoma tissues were obtained from gastrectomy specimens of 129 patients from the department of general surgery, the affiliated hospital of guilin Medical University (guilin, China). there were 87 males and 42 females (mean age 57.6 years; range 22-82 years). Relevant clinical pathologic features (table 1) were all obtained from the patients' files. Patient diagnosis was established pathologically, and no patient had received chemotherapy or radiotherapy prior to surgery. all the operations were performed between January 2006 and December 2007. the cases were selected consecutively on the basis of availability of resection tissues and follow-up data. Furthermore, we also selected another 47 cases of gastric cancer patients who had received neoadjuvant chemotherapy to evaluate the response of hsP22 expression in chemotherapy. these patients were all submitted to a diagnostic biopsy before neoadjuvant chemotherapy and matched tumor specimens were obtained during surgical resection from January 2010 to september 2010. all the specimens from 47 patients had enough residual tumor tissues to evaluate. all tissues specimens were formalin-fixed and paraffin-embedded. tumor stage was classified according to the 7th Union International Cancer Control (UICC) tnM staging system (edge and Compton 2010).
Preoperative chemotherapy the initial diagnosis of 47 patients was done from January 2010 to september 2010. Patients with stage III-IV (M0) gastric cancer were enrolled for neoadjuvant chemotherapy. Pretreatment tumor staging was performed according to a uniform protocol that included endoscopy with endosonography, a Ct scan of the chest and abdomen and diagnostic laparoscopy. all 47 patients were treated with the FOlFOX regimen (leucovorin, 5-fluorouracil and oxaliplatin) (al-Batran et al. 2008 ) and underwent gastrectomy with D2 lymphadenectomy after chemotherapy. neoadjuvant chemotherapy consisted of intravenous infusion of oxaliplatin (85 mg/m 2 , 2 h) and leucovorin (200 mg/m 2 , 2 h), followed by 5-fluorouracil 2,600 mg/m 2 as a 24 h continuous infusion. Cycles were repeated at 2-week intervals for one or two cycles. surgical tumor resection was scheduled 2 weeks after the completion of chemotherapy. there were 11 patients who received one cycle of FOlFOX regimen, while others received two cycles of neoadjuvant chemotherapy.
Immunohistochemistry staining
We used a previously described immunohistochemistry (IhC) procedure (Wang et al. 2013) . Briefly, formalinfixed, paraffin-embedded tissue samples from consenting patients were cut in 4-μm sections and placed on polylysine-coated slides, deparaffinized in xylene, and rehydrated in a series of graded alcohols (100 % alcohol, 95 % alcohol, 80 % alcohol and 70 % alcohol). the tissue slides were then treated with 3 % hydrogen peroxide in methanol for 30 min to quench endogenous peroxidase activity, and the antigens were retrieved in 0.01 M sodium citrate buffer (ph 6.0) using a microwave oven. after 30 min of preincubation in 10 % normal goat serum to prevent non-specific staining, the samples were incubated overnight using a primary antibody, either anti-hsP22 (abcam, #ab89187, UK, dilution 1:200) or anti-MMP-9 (abcam, #ab38898, UK, dilution 1:200), in a humidified container at 4 °C. the tissue slides were treated with a non-biotin horseradish-peroxidase detection system according to the manufacturer's instructions (gene tech). the IhC results were evaluated by two independent investigators blinded to the patients' identity and clinical status. In discrepant cases, a pathologist reviewed the cases, and a consensus was reached.
hsP22 and MMP-9 staining intensities were rated on a scale of 0-3 according to the percentage of positive tumor (0, <5 % positive cells; 1, 5-20 %; 2, 20-50 %; or 3, >50 %). the expression is very low for 0, low for 1, moderate for 2 and high for 3 (Fig. 1 ). hsP22 and MMP-9 expression were classified as negative for scores ≤1 and positive for scores ≥2.
Follow-up
all the patients had follow-up records for more than 5 years. the follow-up deadline was september 2013. Patients had follow-up appointments every 3 months for the first 3 years after surgery, every 6 months for the next 2 years and yearly thereafter. the median follow-up period was 23 months (range 3-82 months) in 129 patients. Recurrence were confirmed by tumor markers levels including Cea, aFP, Ca199, Ca125 and Ca724, B-type ultrasonic inspection every 3 moths and computed tomography (Ct) or magnetic resonance imaging (MRI) every 6 months after gastrectomy. the main causes of death were gastric cancer recurrence. Overall survival (Os) was calculated from the date of surgery to the date of death or last follow-up. Recurrence-free survival (RFs) was defined as from the date of surgery until the date of relapse or from the period of resection to the date of the last observation taken. statistical analysis all statistical analyses were carried out using sPss software (version 16.0; Chicago, Il, Usa). Interdependence between hsP22 expression and clinical data was calculated using the chi-square test and displayed in cross-tables. Correlation of hsP22 expression with MMP-9 expression was calculated by Pearson χ 2 test. Univariate survival analysis was assessed by the Kaplan-Meier method, and the difference in survival curves was analyzed by the log-rank test. significant prognostic factors found by univariate analysis were entered into a multivariate analysis using the Cox proportional hazards model. Multiple comparisons were corrected by using the Bonferroni method. all reported P values were two-sided, and P < 0.05 was considered statistically significant.
Results
the association of hsP22 with clinicopathological variables a total of 129 gastric cancer patients were investigated by immunohistochemistry. hsP22 staining was mainly located in cytoplasm of tumor cells. Overexpression of hsP22 was observed in 82 of 129 (63.6 %) of gastric cancer samples.
according to the results of immunohistochemistry, we correlated hsP22 status in 129 gastric cancer specimens with eight other widely recognized clinicopathologic parameters (table 1) . the expression of hsP22 in gastric cancer was significantly correlated with tumor size (P = 0.002), depth of invasion (P < 0.001), lymph node metastasis (P < 0.001) and tnM stages (P < 0.001), but was not correlated with gender, age, tumor site and grade of differentiation (P > 0.05) (table 1) . notably, the correlation of hsP22 expression with prominent serosal invasion and lymph node metastasis positivity suggested a potential role of hsP22 in increased invasion and metastasis of gastric cancer.
Correlation between hsP22 expression and prognosis
We first performed univariate analysis of traditional clinicopathologic variables for prognosis. the results of the univariate analysis are shown in table 2. significant variables in the Os and RFs analysis included hsP22 overexpression (P < 0.001 and P < 0.001, respectively), larger tumor size (P = 0.016 and P = 0.019, respectively), prominent serosal invasion (P < 0.001 and P < 0.001, respectively) and lymph node metastasis (P < 0.001 and P < 0.001, respectively). Furthermore, to evaluate the independent impact of hsP22 overexpression on Os and RFs, a multivariate Cox regression model adjusted for tumor size, depth of invasion, lymph node metastasis and hsP22 expression was performed. Our results showed that hsP22 expression was an independent prognostic factor for both Os (hR 2.335, 95 % CI 1.335-4.087; P = 0.003) and RFs (hR 2.295, 95 % CI 1.313-4.011; P = 0.004) of patients with gastric cancer. Depth of invasion and lymph node metastasis all had independent prognostic value in the multivariate analysis (table 3) .
the Kaplan-Meier survival analysis revealed that Os and RFs with high hsP22 expression were significantly shorter than those with low hsP22 expression (P < 0.001 and P < 0.001, respectively) (Fig. 2a) . the postoperative median Os and RFs were 23.0 and 19.0 months, respectively. the postoperative median RFs and Os of patients with positive staining of hsP22 were 15.0 and 10.0 months, while there were 37.0 and 36.0 months of those with negative staining of hsP22. For patients with high hsP22 expression, the cumulative 3-and 5-year survival rates were 32.1 and 19.6 %, respectively, which was significantly lower than those for patients with low hsP22 expression (70.6 and 61.2 %, respectively).
to further evaluate the prognostic value of hsP22 expression in different subgroups, patients were stratified according to tumor size (Fig. 2b, c) , depth of invasion (Fig. 2d , e) and lymph node metastasis (Fig. 2f, g ). the expression of hsP22 maintained its prognostic value in predicting shorter Os and RFs in all of these subgroups for except RFs in patients who had larger tumor size (P = 0.052). therefore, it appears that hsP22 expression may serve as a powerful prognostic factor for patients with gastric cancer in different risk groups. hsP22 overexpression predict a poor prognosis independent of tumor invasiveness to further explore the significance of hsP22 expression on tumor invasiveness in gastric cancer, we investigated the relationship of hsP22 and MMP-9 protein expression in gastric cancer.
the rates of hsP22 overexpression were 76.5 and 72.4 % in the more prominent serosal invasion group (t3/ t4) and more frequent lymph node involvement group (n1-3), while there were only 38.6 and 35.5 % in t1/t2 and n0 (P < 0.001 and P < 0.001, respectively) (table 1). In addition, correlation studies showed that hsP22 protein expression was positively correlated with MMP-9 expression in 129 gastric carcinoma tissues. Of 47 patients with low hsP22 expression, 33 patients (70.2 %) had low MMP-9 expression, while 59 of 82 patients (72.0 %) with high hsP22 expression also had high MMP-9 expression (P < 0.001) (Fig. 3) .
We further explored the influence of tumor invasiveness on the prognostic value of hsP22 expression in gastric cancer by using MMP-9 as an indicator for the invasive potential of individual tumor cells. all the patients were stratified into either a low-invasiveness subgroup (low MMP-9 expression; n = 56) or a high-invasiveness subgroup (high MMP-9 expression; n = 73) according to the MMP-9 expression index. Kaplan-Meier survival curves were then plotted to investigate the association between hsP22 expression and survival (Fig. 4) . In the low-invasiveness subgroup, hsP22 overexpression was associated with shorter Os (P = 0.015) and RFs (P = 0.020) compared with the Os and RFs in patients with low hsP22 expression (Fig. 4a) . In the high tumor invasiveness subgroup (Fig. 4b) , patients with hsP22 overexpression were prone to death (P = 0.015) and relapse (P = 0.005). therefore, the expression of hsP22 appears to be a strong postsurgical prognostic parameter for patients with gastric cancer independent of tumor invasiveness.
Response of hsP22 in neoadjuvant chemotherapy the difference in survival observed in patients with gastric cancer prompted us to question whether hsP22 expression was related to administration of chemotherapy. We detected hsP22 expression in diagnostic biopsy materials and matched surgical samples from 47 patients with gastric cancer. hsP22 was expressed in 66.0 % (31/47) of biopsies and 53.2 % (25/47) of resection specimens. neoadjuvant chemotherapy did not alter hsP22 expression between the biopsy and tumor specimens (P = 0.207) (Fig. 5) . In 35 (74.5 %) cases, hsP22 expression was identical in the biopsy and the matched specimens. Five (10.6 %) cases showed upregulation of hsP22 expression, while there were 7 (14.9 %) cases with downregulation of hsP22 expression in the surgical samples compared with the biopsy material.
Discussion
to our knowledge, the associations between hsP22 overexpression and the prognosis of gastric cancer have not been reported. this study is to investigate the impact of hsP22 overexpression on the prognosis of gastric cancer based on a relatively large number of clinical samples. In the present study, hsP22 expression levels were investigated in 129 gastric carcinoma tissues by immunohistochemistry. We found that hsP22 expression was significantly associated with depth invasion, lymph node metastasis and clinical stages. In addition, the Kaplan-Meier survival analysis b-g) revealed that the survival times (Os and RFs) of gastric cancer patients with high hsP22 expression were significantly shorter than those with low hsP22 expression. the prognostic value of hsP22 expression in different subgroups according to tumor size, depth of invasion and lymph node metastasis was also estimated, which appears that hsP22 expression may serve as a powerful prognostic factor for patients with gastric cancer in different risk groups. Moreover, the multivariate Cox model analysis indicated that hsP22 expression status was an independent factor for both prognosis indexes (Os and RFs) in gastric cancer. this finding suggests that hsP22 plays an important role in tumor prognosis and that hsP22 could be a potential target for the prevention and treatment of gastric cancer. the results of this study were consistent with previously reported results. In several investigations, it has been shown that the abnormal expression of hsP22 in cancer cells is associated with tumor progression. Modem et al. (2011) found that hsP22 regulates sam68 expression, and the ratio of sam68 to hsP22 may determine the proliferative potential of glioblastoma cells. additionally, Wadhwa et al. (2010) showed that Drosophila small mitochondrial hsP22 expression in human cancer cells could increase their malignant properties and resistance to a variety of anticancer drugs through the way that inactivates wild type tumor suppressor protein p53. Furthermore, smith et al. (2000) reported that hsP22 was expressed in melanoma cell lines and primary melanoma tissues at levels higher than in normal melanocytes and could involve activation of growth-associated transcription factors such as e2F and/or cyclin-dependent kinase such as cdk4.
It has been known that degradation of extracellular matrix (eCM) was a signal for the beginning of invasion and metastasis, and MMPs are important molecules involved in eCM degradation during invasion and metastasis (nelson et al. 2000) . Chu et al. (2011) reported that cancer MMP-9 was significantly correlated with depth of invasion and lymph node metastasis, and MMP-9-positive gastric cancer patients had worse outcomes than those with MMP-9-negative tumors. Zhao et al. (2010) found that MMP-9 targeted Rna interference was able to successfully suppress MMP-9 expression and inhibit cell growth and invasion of sgC7901 gastric cancer in vitro and in vivo. Our results demonstrated that the expression of hsP22 and MMP-9 were correlated with each other, indicating higher invasive and metastasizing activity in hsP22 high-expression cancer cells. In addition, hsP22 was highly expressed in depth of invasion, especially in t3 and t4 carcinomas. as far as lymph node status was concerned, the patients . Kaplan-Meier survival estimates and log-rank tests were used to analyze the association between hsP22 expression and overall survival or recurrence-free survival in patients with low invasiveness (low MMP-9; n = 56) or high invasiveness (high MMP-9; n = 73) with lymph node metastasis tend to show elevated hsP22 expression. Moreover, the expression of hsP22 could be a strong postsurgical prognostic factor for gastric cancer patients independent of tumor invasiveness. Collectively, hsP22 expression in gastric cancer promoting tumor aggressiveness suggests that hsP22 could be a feasible target in cancer therapy.
Furthermore, we investigated the response of hsP22 in neoadjuvant chemotherapy and found that neoadjuvant chemotherapy did not alter hsP22 expression between the biopsy and tumor specimens of gastric cancer. hsP22 overexpression in various types of cancer cells possesses a carcinogenesis and anti-apoptotic activity (gober et al. 2005) and resistance to a variety of anticancer drugs (Wadhwa et al. 2010) . Moreover, there is no definite evidence of the effectiveness of neoadjuvant chemotherapy in resectable gastric cancer, in terms of improvements in patient survival (Wu et al. 2007 ). In agreement with this viewpoint, our results confirmed that the hsP22 levels remain largely unchanged in chemotherapeutic effect, which afforded us the opportunity to make an important observation that the expression of hsP22 levels in the tumors was stable, no matter whether it received neoadjuvant chemotherapy or not. taken together, targeting hsP22 with chemical inhibitors could be considered in the treatment of gastric cancer, especially when hsP22 was highly expressed in gastric cancer.
In summary, we demonstrated that overexpression of hsP22 may play an important role in tumor invasion, metastasis and prognosis and could work as a promising target for prognostic prediction. Determination of hsP22 expression levels may help to identify high-risk gastric cancer patients and thus aid the selection of appropriate therapies. Further studies are warranted to more firmly establish this supposition.
